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Abstract 
Manufacturers of veterinary vaccines frequently incorporate animal-based batch release safety tests into their quality assurance
monitoring protocols to meet their internal quality standards and to conform to government regulatory requirements. These tests
are conducted by vaccinating target species animals or laboratory animals with a single dose or multiple doses of the test batch,
and observing the vaccinated animals for signs of local or systemic adverse reactions. Manufacturers, standard-setting bodies, 
animal welfare advocacy groups, and regulatory agencies are actively investigating alternative methods to reduce their reliance
on animal-based methods for batch release safety testing. Approaches which have been implemented or proposed include 
harmonizing technical requirements, developing in vitro tests, refining the existing animal tests, improving adverse reaction 
monitoring (vaccinovigilance), and improving manufacturing methods and quality controls to reduce batch-to-batch variability. 
An approach, known as the consistency approach, is increasingly being acknowledged as a potentially viable alternative to 
animal-based batch release tests for vaccines. This paper will provide an overview of currently utilized batch release safety tests 
for veterinary vaccines, the associated regulatory requirements, and some potentially acceptable alternative approaches for 
reducing, refining, and replacing the use of animals in these tests. 
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1. Introduction 
Post-licensing batch release safety tests for veterinary vaccines are quality control tests that are conducted on 
samples from individual batches of a licensed (registered) vaccine, as part of a comprehensive quality assurance 
monitoring system [2, 6, 7, 8, 28, 29, 30, 39, 43]. These tests serve as broad-spectrum bioassay to assess the 
biological properties of each batch of a licensed (registered) vaccine, to detect any signs of abnormal toxicity that 
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may have been overlooked by manufacturing controls and in-process tests, which focus on specific quality 
parameters.  
Veterinary vaccines are complex mixtures of biological components, and are subject to some inherent batch-to-
batch variability that might affect the safety of the product. Accordingly, in addition to conducting pre-licensing 
safety testing, manufacturers are also generally required to conduct animal-based safety tests on each batch of 
finished product prior to release [6, 10, 43, 44], unless it can be clearly demonstrated that this end-product testing is 
not necessary [10, 25]. These tests are conducted on the finished vaccine (bulk containers or final bottles), and can 
therefore potentially assess the cumulative effects of any minor deviations in the formulation of the product. The 
batch safety tests are ordinarily conducted by the manufacturer, and are not usually repeated by the regulatory 
agencies, except possibly to conform with import requirements [37, 40]. 
Table 1 provides some examples of the potential applications of in vitro or in vivo batch release safety tests for 
veterinary vaccines.
Table 1. Examples of vaccine safety parameters that could be assessed by in vitro or in vivo batch release 
safety tests.
Residual viable vaccine organisms in inactivated viral or bacterial vaccines 
Contamination of the finished product by pathogenic extraneous agents 
Elevated levels of bacterial endotoxin (lipopolysaccharide) in vaccines derived from Gram negative bacteria 
Elevated levels of biologically active tetanus neurotoxin in tetanus toxoid vaccines 
Increased neurovirulence in attenuated live virus vaccines
Residual neurovirulence in inactivated virus vaccines 
Elevated levels of residual formaldehyde in inactivated bacterial vaccines. 
In comparison with pharmaceutical products, finished product testing is relatively more important for veterinary 
vaccines because these products are complex biological products which are comprised of a mixture of relatively 
uncharacterized antigens originating from pathogenic organisms and their potentially toxic by-products [2, 28, 29, 
30, 35, 36, 39]. In comparison with a pharmaceutical product, the protective components and potentially toxic 
factors in a veterinary vaccine are much less well characterized, and the composition of the finished vaccine is less 
uniform than a pharmaceutical product.  
Although the manufacturing methods for veterinary vaccines are precisely controlled, due to the nature of the 
products, it is possible that there could be undetected variations in the composition of the finished vaccine that might 
adversely affect product safety. These batch-to-batch variations could involve toxic elements or contaminants that 
are difficult to detect by the manufacturers’ in vitro quality control testing. Veterinary vaccines also tend to be 
relatively less purified than vaccines intended for human use, which leads to a higher risk for contamination by toxic 
elements than comparable human vaccines.  
Consequently, in addition to meeting licensing requirements through comprehensive pre-licensing safety, 
efficacy, and quality testing, and conformance with good manufacturing practice (GMP) principles or equivalent 
standards, as a supplemental precautionary measure, veterinary vaccines are usually also required to undergo quality 
control tests to verify the potency and safety of each batch of licensed vaccine.  
The current regulatory standards for veterinary vaccines in Europe, the United States, and other countries include 
general provisions for development, validation, and approval of alternative methods to reduce, refine, or replace the 
use of animals for batch release safety testing [10, 11, 12, 24, 25, 42, 43]. In Europe, there are specific provisions for 
elimination of animal-based batch release safety tests for veterinary vaccines, if other compensatory regulatory 
controls and quality control tests are implemented to provide assurances about batch-to-batch consistency and safety 
of the product [10, 11, 12, 25]. This strategy for improving quality control and implementing the 3Rs is known as 
the consistency approach [11, 16]. 
This paper will provide an overview of currently utilized batch release safety tests for veterinary vaccines, and 
the associated regulatory requirements. It will also review some potentially acceptable alternative approaches for 
reducing, refining, and replacing the use of animals in these tests. 
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2. Regulations and technical standards 
To meet licensing (registration) requirements, veterinary vaccines must be shown in comprehensive pre-licensing 
testing to be pure, potent, safe and effective when used in the target species according to the approved label 
recommendations [6, 7, 9, 10, 21, 23, 24, 26, 44, 45]. Manufacturers are also required to demonstrate that they can 
consistently produce batches that meet the established quality control criteria [6, 7, 9, 10, 21, 44, 45].  
The regulatory requirements for batch release safety testing are outlined in legislation, regulations, and technical 
standards that are implemented by government regulatory agencies, such as the United States Department of 
Agriculture Center for Veterinary Biologics (USDA CVB) which regulates veterinary vaccines in the United States 
[43], and the European Medicines Agency (EMA) which serves as the centralized product registration agency for 
member states of the European Union [7]. The regulatory agencies (competent authorities) of other countries tend to 
have regulatory frameworks based on either the European or American standards.  
Several standard-setting bodies also play an important role in establishing common technical standards for 
veterinary vaccines. Examples include the World Organisation for Animal Health-Office Internationale des 
Epizooties (OIE) [40], the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation 
Scheme (PIC/S), the Veterinary International Cooperation for Harmonization (VICH) [41], and the International 
Association for Biologicals (IABS) [34].  
The European requirements for batch release safety testing are outlined in Eudralex Volume 7 Scientific 
guidelines for medicinal products for veterinary use [7], the European Pharmacopoeia (Ph. Eur.) General 
Monograph on Vaccines for Veterinary Use [10], and individual Ph. Eur. Monographs for vaccines for specific 
diseases, such as anthrax [12], salmonellosis [13], tetanus [14], and vibriosis of salmonids [15].  
The USDA CVB requirements for batch release safety testing are based on the Virus Serum Toxin Act, the 
United States Code of Federal Regulations Title 9 Animal Products (9 CFR), and a series of associated guidance 
documents (Veterinary Services Memorandums, Center for Veterinary Biologics Public Notices, and Supplemental 
Assay Methods) [42, 43]. 
3. Good manufacturing practices 
The manufacturing standards and associated inspection procedures for veterinary vaccine manufacturing facilities 
are outlined in various regulatory documents and technical documents, including the 9 CFR [44], the Rules 
Governing Medicinal Products for the European Union [7] and harmonized GMP protocols established by the 
Pharmaceutical Inspection Convention (PIC) and the Pharmaceutical Inspection Co-operation Scheme (PIC 
Scheme), which function jointly as the PIC/S [41]. The PIC/S is an independent standard-setting body whose 
mission is "to lead the international development, implementation and maintenance of harmonised Good 
Manufacturing Practice (GMP) standards and quality systems of inspectorates in the field of medicinal products" 
[41]. 
4. Animal-based batch safety testing protocols – 9 CFR and Ph. Eur. 
Manufacturers, in accordance with standardized testing protocols that are documented in an approved production 
outline or special outline, or product master file, ordinarily conduct batch release safety tests. Manufacturers located 
in the United States or countries whose system is based on 9 CFR standards use production outlines and special 
outlines. A product master file is prepared by manufacturers located in the European Union or countries whose 
regulatory system is based on European Union Good Manufacturing Practices (GMP) standards and the Ph. Eur. The 
formats for the production outline and product master file are different, however they serve the same purpose – to 
document the materials and methods that are used to manufacture and test the regulated product.  
For products manufactured to conform to requirements of the 9 CFR, the currently employed in vivo batch 
release safety tests involve administration of vaccine to small numbers of animals of the species for which the 
product is intended (target species), or laboratory animals [44, 45]. Batch release safety tests conducted in the target 
species (i.e., dogs, cats, cattle, horses, pigs) generally use two animals, while safety tests conducted in laboratory 
animals generally use eight mice or two guinea pigs. If a product may be used in various ages, classes, or species of 
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animals, the tests are ordinarily conducted in the youngest age animal that would receive the vaccine since they 
would probably be the most susceptible to adverse effects.  
To meet the 9 CFR requirements, the test dose for products tested in the target species is typically either a single 
(1x) dose, a 2x overdose (for inactivated vaccines), or a 10x overdose (for live attenuated vaccines) [44, 45]. The 2x 
and 10x overdose tests are intended to increase the likelihood of detecting unsatisfactory serials by (1) amplifying 
the effects of any toxic factor, and (2) increasing the volume of the innoculum for enhanced detection of low level 
contamination with residual viable vaccine organisms or infectious contaminants. A 1x dose is typically used when 
the batch safety test is conducted as the preliminary phase of an animal potency test. The test vaccine is ordinarily 
administered by the recommended route(s); however it may be administered by other routes or to additional species 
for specific purposes. For example, inactivated rabies vaccines are tested by intracerebral inoculation of mice and 
rabbits as well as intramuscular administration in the most susceptible target species [44]. In most protocols, only 
one test dose is administered, however some protocols include a booster dose. For overdose tests, the vaccine is 
administered at multiple injection sites.  
Since the protective immune responses in fish are not as well characterized as those in domestic mammals and 
poultry, the batch release protocols for fish vaccines often require testing groups of vaccinates and control fish in a 
vaccination-challenge test to demonstrate protection from challenge as a measure of potency through a parameter 
known as relative percent survival (RPS) [15, 31, 37]. To minimize the numbers of animals required for batch 
release testing, the vaccinated fish that are used in potency testing can also be used to generate safety information, 
based on their response to vaccination during the pre-challenge phase of the batch release potency test [15, 31, 37]. 
The sample sizes for batch safety tests are relatively small to minimize the use of experimental animals. To 
conform with the 9 CFR and the Ph. Eur., the batch release safety tests for products intended for use in mammals are 
usually conducted in two animals, while products intended for use in birds or fish are tested in 10 or more birds or 
fish [8, 10, 11, 12, 13, 14, 15, 21, 37, 44, 45]. In some safety test protocols, the batches are tested in the target 
species at the recommended dose during the post-vaccination phase of an animal batch release potency test. It has 
been noted that, when safety tests are conducted by vaccinating target species animals according to the label 
recommendations, there is usually no major animal suffering associated with these tests [3]. 
In Europe, batch release safety testing for veterinary vaccines usually involves administration of a 2x overdose of 
an inactivated vaccine or a 10x overdose of a live vaccine by the recommended route [12, 13, 14, 15]. To meet the 
Ph. Eur. requirements, the tests must be conducted in target species animals, using at least two mammals or 10 birds 
or fish. In Europe, the batch release safety tests are not ordinarily conducted in laboratory animals.  
The observation period for batch release safety tests, to conform to 9 CFR and Ph. Eur. Requirements, is 
usually 7, 14, or 21 days. During the observation period, animals are examined daily for evidence of local or 
systemic adverse reactions [10, 12, 13, 14, 15, 44].  
Some regulatory agencies, including the USDA CVB and the Canadian Food Inspection Agency Canadian Centre 
for Veterinary Biologics (CFIA CCVB), allow batch release safety testing in species other than the target species 
(e.g., sheep, laboratory mice, rabbits, guinea pigs, chickens) [6, 44, 45]. The tests conducted in laboratory animals 
are primarily intended to detect significant changes in acute toxicity, rather than being a precise assessment of local 
injection site reactions. Consequently, the test dose for laboratory animals is standardized at a predetermined 
volume, as prescribed in regulations and guidance documents, and is based on established generic protocols, rather 
than requiring manufacturers to calibrate an appropriate test dose for each product. The test dose is usually less than 
the dose for the target species, and in some protocols, a different route of administration is used. For example, to 
conform to the 9 CFR 113.33 requirements, bacterins may be tested in mice by administration of 0.5 mL of the test 
bacterin via the subcutaneous or intraperitoneal route [44].
Title 9 of the CFR includes standard requirement protocols for batch release safety tests to be conducted in target 
animals or laboratory animals [44]. Target animals and laboratory animals may be used to test some products. 
Manufacturers may implement the standard tests as described in the 9 CFR, or they may implement alternative 
methods that must be documented and approved in the production outline.
To reduce the use of animals for regulatory testing, both the 9 CFR and the Ph. Eur. have provisions for 
conducting safety tests on bulk samples from bulk containers that are used to formulate multiple batches of vaccine 
[10, 44]. Where multiple batches are prepared from the same bulk, if the safety tests are satisfactory on the first 
batch, the tests may be omitted for subsequent batches produced from the same bulk [10, 44, 45]. Similarly, if 
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animal-based tests are used for batch release potency tests, the post-vaccination phase of the batch potency test can 
be used to generate batch safety data [10, 44, 45]. 
5. World Organisation for Animal Health – Office Internationale des Epizooties (OIE) Manual of Diagnostic 
Tests and Vaccines for Terrestrial Animals Part 2 
Part 2 of the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals [40] describes (1) specific 
test methods for diagnostic tests for infectious agents, and (2) procedures that have been adopted for preparing and 
testing veterinary vaccines and diagnostic tests for use in prevention or diagnosis against infectious agents that are 
of concern for international trade in livestock and poultry. 
In the OIE Manual, the prescribed safety tests for inactivated vaccines involve inoculating two animals with a 2x 
overdose via each recommended route. A 10x overdose is recommended for live vaccines. For some vaccines, the 
tests may be conducted in laboratory species (i.e., mice or guinea pigs) however the OIE Manual does not specify 
precise testing protocols. Generally, the OIE batch release safety test protocols recommend using seronegative 
animals and the test animals are observed for 14 days for signs of local or systemic reactions, because one of the 
main objectives of the OIE vaccine tests is to identify residual infectious material or extraneous agents in attenuated 
or inactivated vaccines. 
Some OIE product batch release safety testing protocols recommend testing in laboratory animals, including 
administration by the intracerebral route in mice or chicks, to test for presence of neuropathogenic viruses such as 
Newcastle Disease virus, rabies virus, and Japanese encephalitis virus. However, the OIE Manual also allows for 
substitution of alternative methods where appropriate. For example, safety tests to detect residual live rabies virus in 
batches of inactivated rabies virus vaccines may be carried out either by intracerebral injection into mice, or 
inoculation of cell culture.  
To conform to the OIE Manual [40], batch release safety tests for live attenuated rabies vaccines must be carried 
out on each lot of vaccine in the intended host species, because there are species differences in susceptibility to 
rabies virus infection and clinical disease. According to the prescribed protocol, at least three, preferably five or six 
animals of the intended host species should be given a dose equivalent to 10 times the recommended field dose, by 
the recommended route of administration. The animals should be observed for 90 days for adverse reactions 
attributable to the vaccine. 
6. International harmonization 
Regulatory agencies, international standard setting bodies, and industry associations are actively involved in 
development of harmonized technical standards for veterinary vaccines, including alternatives to animal testing [17, 
21, 26, 27, 34, 36, 37, 38, 39, 40, 44, 45, 46]. Current activities include applied research on humane endpoints 
[3,4,5], standardization of laboratory test methods [46], production and exchange of reference reagents [45, 46], 
development of harmonized standards for batch release safety testing [46], information exchange [34, 35, 37], and 
publication of technical reference documents [4, 38, 39, 40, 41]. Table 2 lists some of the groups involved in these 
initiatives. 
7. Predictive capacity of current animal-based batch release safety methods 
Although animal-based batch release safety tests would be expected to generate some level of supplemental 
information about the safety of a specific batch of vaccines, the incremental added value of a specific test is difficult 
to quantify in practical terms. The overall utility of an animal-based batch release safety test, its predictive 
capabilities, and its relative importance for quality monitoring depend on several factors, including the following:  
x Inherent safety of the product, and likelihood of producing batches with abnormally high toxicity 
x Consistency of manufacturing processes 
x Potential batch-to-batch variability of the specific product 
x Reliability of manufacturing controls, in-process tests, or finished product tests 
x Potential impacts of inadvertent release of unsatisfactory batches 
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Table 2. Examples of organizations involved in the development and implementation of harmonized technical 
standards and regulatory approval procedures for veterinary vaccines. 
World Organisation for Animal Health - Office Internationale des Epizooties (OIE) 
Veterinary International Cooperation for Harmonisation of Technical Requirements for Veterinary Medicinal Products (VICH) 
European Directorate for the Quality of Medicines & HealthCare (EDQM) 
Paul Ehrlich Institute (PEI) 
Committee of the Americas for Veterinary Medicines (CAMEVET).   
International Association for Biologicals (IABS) 
European Centre for the Validation of Alternative Methods (ECVAM) 
European Partnership for Alternative Approaches to Animal Testing (EPAA) 
National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) 
Institute for International Cooperation in Animal Biologics (IICAB) 
International Federation for Animal Health (IFAH) 
Pharmaceutical Inspection Convention (PIC) and the Pharmaceutical Inspection Co-operation Scheme (PIC Scheme), collectively 
known as PIC/S. 
In vivo batch release safety tests have been widely used for many years, and it would be expected that they would 
provide important safety information. Nonetheless, because batch release test results are generally conducted in 
manufacturer’s quality control laboratories, the individual test reports and summary data tends to be retained in 
manufacturers’ confidential product files, and used only for reporting batch release test results to regulatory 
agencies. Consequently, there is relatively little published summary data available to characterize the actual 
predictive value of the animal-based batch release safety tests that are currently being used for veterinary vaccines. 
In the absence of supporting data, several authors have questioned the predictive capacity of these test protocols, and 
recommended that alternative methods be employed [1, 16, 17, 18, 19, 20, 21, 22, 31, 32, 34, 37, 42, 43].   
The authors note the following main limitations of the currently utilized in vivo batch release safety tests as 
follows: 
x Small sample sizes (as few as two animals per test), which may limit the statistical validity 
x Potential variability of individual animal responses to vaccination 
x Rudimentary pass/fail criteria (observation of clinical signs, visible/palpable injection site reactions, survival) 
x Lack of validation data for laboratory animal tests to establish the biological relevance, statistical validity, and 
predictive value of the laboratory animal test. This leads to uncertainty about the correlation of the laboratory 
animal test results with potential effects in the target species.  
The above factors may limit the capacity of the animal-based tests to detect unsatisfactory batches, except for 
those batches with major deviations in the product composition due to formulation errors or introduction of 
contaminants.  
Due to animal welfare concerns, which are compounded by questions about the biological relevance of the tests, 
and uncertainty about their predictive value, the appropriateness of animal-based batch release safety tests is 
increasingly being questioned [1, 16, 17, 18, 19, 20, 21, 22, 25, 28, 31, 32, 33, 34, 37, 42, 43]. To address this issue, 
several groups have proposed that the current test methods be refined or replaced by alternative methods such as the 
consistency approach [19], for reasons such as those listed in Table 3.
8. Alternative approaches  
As part of a broadly based “3R” initiative to reduce, refine, and replace the use of animals for research and 
regulatory testing, proceedings from several international forums have recommended that industry and regulatory 
agencies should implement alternative methods to reduce, refine, and replace the use of animals in batch release 
testing of veterinary vaccines [1, 3, 16, 17, 18, 19, 20, 21, 22, 28, 31, 32, 33, 34, 37, 42, 43]. Considerable progress 
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has been made toward improvement of manufacturing standards and development of new test methods to 
characterize veterinary vaccines.  These advances have helped to reduce and refine animal-based safety tests for 
batch release. However, animal-based batch release safety tests are still employed for many products – frequently as 
a component of animal-based batch release potency tests.  
Table 3. Reasons cited for moving to reducing, refining or (preferably) replacing animal-based batch release 
safety tests for veterinary vaccines 
Improved consistency of veterinary vaccine manufacturing procedures has diminished the batch-to-batch variability of licensed 
vaccines
Lack of validation data for current batch release safety tests to characterize their predictive value for detecting unsatisfactory batches 
Availability of improved in vitro methods to assess product composition and verify freedom from microbial contamination 
Low overall rate of adverse reactions associated with use of licensed veterinary biologics 
Animal welfare concerns for test animals 
The European and American regulatory systems both include provisions for approval of 3R alternatives to 
reduce, refine, or replace the use of animals for post-licensing batch release safety testing of veterinary vaccines [10, 
25, 44, 45]. Manufacturers may implement batch release test protocols based on standard requirements, as listed in 
the Ph. Eur. or 9 CFR; or they may propose alternative test methods in the licensing (registration) documentation.  
The Ph. Eur. Monograph 62 (Vaccines for Veterinary Use) states that the routine application of the batch release 
safety test may be waived for established vaccines provided the consistency of production has been demonstrated for 
at least 10 consecutive batches [10].  
The EMA has informed manufacturers, through a guidance document [25], that the EMA will consider requests 
for exemptions to eliminate the requirement for in vivo batch release testing, provided the manufacturers can furnish 
supporting data to demonstrate consistency and safety for multiple consecutive batches.  
Manufacturers in the United States, Canada, and other countries can also propose alternative methods and request 
exemptions from prescribed standard test requirements under existing regulations and policies [6, 44, 45]. For 
example, the United States 9 CFR Chapter 113 (Standard Requirements) includes provisions for authorizing 
exemptions from standard requirements (see 9 CFR 113.4 Exemptions to Tests) [44]. Manufacturers that are 
regulated by the USDA CVB are required to document their manufacturing and testing procedures in an approved 
production outline or special outlines that can either cite standard batch safety testing protocols as outlined in 9 
CFR, or describe alternative methods [44, 45]. For regulatory approval, the proposed alternative methods would 
need to be biologically relevant and appropriately validated. 
9. Regulatory approval procedures for European Union – consistency approach 
The EudraLex guidelines entitled “Rules Governing Medicinal Products in the European Union Volume 7 
Scientific Guidelines” outline the requirements for medicinal products for veterinary use [7]. A series of 
corresponding European Pharmacopoeia (Ph. Eur.) notices and monographs [8, 9, 10, 11, 12, 13, 14, 15] describe 
the technical specifications for licensing veterinary vaccines in European Union countries through the centralized 
procedure that is administered by the EMA, including standards for pre-licensing safety testing and post-licensing 
safety testing. The Ph. Eur. notices and monographs also outline the procedures to follow to request an exemption 
from batch release safety testing [10, 11). The requirements are further clarified in a Position Paper [25]. 
The Ph. Eur. Chapter 5.2.6 (Evaluation of Safety of Veterinary Vaccines and Immunosera) [9], describes 
recommended protocols for conducting comprehensive pre-licensing laboratory safety tests under the following 
headings:  
x Safety of administration of one dose  
x Examination of reproductive performance  
x Safety of one administration of an overdose (2x for inactivated vaccines and 10x overdose for live attenuated 
vaccines)
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x Safety of repeated administration of one dose; residues; adverse effects on immunological functions, and adverse 
effects from interactions  
Chapter 5.2.6 of the Ph. Eur. also lists additional special requirements for testing live vaccines under the 
following headings:  
x Spread of the vaccine strain;
x Dissemination in vaccinated animal;  
x Increase in virulence; biological properties of vaccine strain; and  
x Recombination or genomic re-assortment of the vaccine strain [9].
Specific post-licensing batch release safety testing requirements are noted in Chapter 5.2.9 (Evaluation of Safety 
of Each Batch of Veterinary Vaccines and Immunosera) [8]. Additional information is provided in individual 
monographs for each major class of veterinary vaccine, such as vaccines for anthrax [12], salmonellosis [13], 
tetanus [14], and vibriosis in salmonids [15]. These monographs typically specify that post-licensing safety tests 
must be conducted in target animals, by administering a 2x or a 10x overdose to either two or 10 test animals, 
depending on the species. Tests in mammals require two animals per test. Tests in birds and fish require at least ten 
birds or fish. Tetanus vaccines are an exception, as they are tested in five guinea pigs, rather than using the target 
species [14]. For licensing (registration) in Europe, to meet the requirements of the Ph. Eur. monographs, all 
products must ordinarily be tested in the target species, unless a waiver has been granted, as noted below. 
The Ph. Eur. includes guidance in a General Notice, which allows for use of alternative methods of analyses [11]. 
In addition, the Ph. Eur. General Monograph on Vaccines for Veterinary Use [10] includes the following description 
of the circumstances where the consistency approach may be implemented: 
“It is recognized that in accordance with the General Notices (section 1.1. General statements), for an established 
vaccine the routine application of the safety test will be waived by the competent authority in the interests of animal 
welfare when a sufficient number of consecutive production batches have been produced and found to comply with 
the test, thus demonstrating consistency of the manufacturing process. Significant changes to the manufacturing 
process may require resumption of routine testing to re-establish consistency. The number of consecutive batches to 
be tested depends on a number of factors such as the type of vaccine, the frequency of production of batches and 
experience with the vaccine during development safety testing, and during application of the batch safety test. 
Without prejudice to the decision of the competent authority in light of information available for a given vaccine, 
testing of 10 consecutive batches is likely to be sufficient for most products. For products with an inherent safety 
risk, it may be necessary to continue to conduct the safety test on each batch” [10].
A position paper of the EMEA Committee for Veterinary Medicinal Products (CVMP) outlines the specific data 
requirements for removing the target animal batch safety test for immunological veterinary products in the European 
Union [25]. The CVMP guidance document [25] cites the provisions in the Ph. Eur. General Monograph on 
Vaccines for Veterinary Use [10]. It explains that the option of waiving this batch release safety testing requirement 
relies on the assurances that are provided by comprehensive pre-licensing safety testing to meet the current 
European Union requirement for pre-licensing safety tests (single dose, overdose, repeat dose), as well as 
documented consistency of the manufacturing process, and a retrospective analysis of batch release test results and 
pharmacovigilance data to demonstrate the overall safety of the product and the reliability of other controls. An 
independent third party expert report must be filed in support of the application [25]. The expert opinion must 
address topics such as the inherent variability of the product, the intrinsic safety margin, post-licensing 
pharmacovigilance data, and pertinent validation data to provide the necessary assurance that the product would 
always be manufactured to an acceptable level of quality and safety [25].
10. Discussion 
The current animal-based batch release safety tests probably serve an important precautionary function for some 
veterinary vaccines, however they have some inherent deficiencies that limit their utility. Without systematic 
validation data, it is difficult to assess the predictive value of these tests. Consequently, manufacturers, regulators, 
and animal welfare advocacy groups have shown considerable interest in developing alternatives to the use of 
animals for these tests, such as the consistency approach. Continued progress toward development and adoption of 
alternative methods depends on several factors, as noted below.  
244  Glen Gifford et al. / Procedia in Vaccinology 5 (2011) 236 – 247244   Glen Gifford et al. /  Procedia in Vaccinology  5 ( 2011 )  236 – 247 
A key prerequisite will be implementation of appropriate comprehensive manufacturing controls to ensure 
consistency of manufacturing processes and uniformity of the end product. Biologically relevant test methods and 
reference standards will need to be developed and validated, preferably through collaborative efforts involving 
manufacturers and regulatory agencies. It will also be important for regulatory agencies to develop clear, 
harmonized parameters for approval of alternative methods. This will help address concerns among manufacturers 
and the international regulatory community about the risk of implementing changes that might lead to inadvertent 
release of unsafe batches of veterinary vaccines. 
The European veterinary vaccine regulations and technical standards clearly define the documentation 
requirements and approval procedures for the consistency approach. In other regions, the consistency approach 
could also be applied on a case-by-case basis, provided sufficient supporting data is available; however, the 
acceptance criteria for implementation of alternative methods for replacement of animal safety tests are not clearly 
defined.  
It is likely that improved in vitro safety tests will become available in the future, especially if (1) manufacturers 
are encouraged to work collaboratively to develop alternatives such as improved manufacturing controls, improved 
vaccinovigilance, and in vitro tests as part of a consistency approach, and (2) the manufacturers have some 
assurance that these alternative approaches would be acceptable to meet international regulatory requirements.  
Another important element will be to establish rigorous pre-licensing safety testing protocols and post-licensing 
quality controls, such as GMP or equivalent standards. It will also be important to establish rigorous batch safety test 
pass/fail criteria with clearly defined maximum tolerances for key product components. For example, production 
outlines for bacterial vaccines should clearly define upper limits for key product components such as total antigen 
content, endotoxin levels, or potency. These limits should be within the ranges that were shown to be safe in pre-
licensing safety testing. 
When considering modifications to existing regulatory controls and manufacturing practices, manufacturers and 
regulatory agencies are proceeding cautiously, because they are accountable for implementing the appropriate 
science-based regulations and corresponding science-based quality controls to help ensure that the regulated 
products are as safe as possible. Although manufacturers and regulators recognize the need to conform to 3R 
principles and encourage development of alternative methods, they must also fulfil their fundamental regulatory 
obligations. Vaccine manufacturers are understandably reluctant to invest in development of alternative methods 
unless there is some reassurance that the changes in test procedures would not diminish the overall quality of 
veterinary vaccines and that they would be sufficient to meet international regulatory requirements.  
There is currently very little publicly available data on the predictive value of the currently employed safety tests, 
despite the fact that some of these tests have been used to test numerous batches of vaccine over an extended period 
of time. These tests may, therefore, not have appropriate baseline references for validation of alternative methods. 
Conversely, there is also a risk that the predictive value of some of the currently utilized animal-based tests has been 
underestimated. An increased availability of summary information on the currently used safety assessment 
procedures would greatly assist the decision process. Manufacturers and regulatory agencies should, therefore, be 
encouraged to conduct a retrospective review of their collective experiences with batch release safety tests. This 
would provide baseline data and a context for discussions regarding the utility of specific currently used tests, as 
well as establishing a benchmark against which future modifications could be assessed. 
The principal regulatory agencies in the countries where international manufacturing facilities are located, and 
the regulatory agencies of importing countries, can influence the development and adoption of alternative methods. 
This can be accomplished through proactive information sharing and collaboration to promote development, 
validation, and implementation of alternatives to reduce, refine, and replace the use of animals for batch release 
safety tests for veterinary vaccines.
In some circumstances, such as for those types of products that have demonstrated a high level of batch-to-batch 
consistency and freedom from adverse events, it may be feasible to eliminate the traditional animal-based safety 
tests, and replace them with alternative methods of characterizing the uniformity and safety of each batch and 
freedom from deleterious factors. In the future, it may also be possible to collaboratively develop in vitro bioassays 
that utilize cell cultures, blood samples or biopsy specimens to measure specific factors or assess non-specific 
cytotoxicity, rather than relying on animal testing.  
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Timely regulatory review and approval of alternative approaches should be identified as a high priority activity 
for regulatory agencies, and consideration should be given to reducing or waiving the applicable regulatory fees, if 
the fees are a significant impediment to implementation of the necessary regulatory approvals.  
Despite progress in developing alternative methods, in vivo batch release safety tests will likely continue to be 
required for some classes of products, especially those that are potentially hazardous, and for which the potential 
toxicity-eliciting factors are not known. In situations where animal safety testing is unavoidable, regulatory agencies 
should continue to encourage development and adoption of the most biologically relevant and humane batch release 
safety test protocols. In these circumstances, the batch release safety tests should be conducted in target animals or 
laboratory animals, using fully validated test protocols with appropriate humane endpoints. 
In the longer term, once useful alternatives are identified and validated, the pertinent legislation, regulations, and 
technical guidance should be amended to facilitate adoption of appropriate alternative methods, and to minimize and 
eventually eliminate use of redundant or obsolete animal-based batch release safety tests. The eventual objective 
should be global standardization of the technical requirements for development and validation of batch release 
safety testing of veterinary vaccines and timely adoption of appropriate manufacturing controls and alternative in 
vitro test methods as a component of a consistency approach.  
Continued future progress toward reduction, refinement, and replacement of animals for safety testing of 
veterinary vaccines will require an ongoing commitment and collaboration from industry, regulators, and animal 
welfare advocacy groups to address the technical, regulatory, and financial challenges.
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